Moleculin Biotech (MBRX) Enterprise Value (2016 - 2025)
Moleculin Biotech (MBRX) has 10 years of Enterprise Value data on record, last reported at -$6.7 million in Q3 2025.
- For Q3 2025, Enterprise Value rose 28.73% year-over-year to -$6.7 million; the TTM value through Sep 2025 reached -$6.7 million, up 28.73%, while the annual FY2024 figure was -$4.3 million, 81.83% up from the prior year.
- Enterprise Value reached -$6.7 million in Q3 2025 per MBRX's latest filing, up from -$7.6 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$4.3 million in Q4 2024 and bottomed at -$86.3 million in Q1 2021.
- Average Enterprise Value over 5 years is -$37.4 million, with a median of -$32.2 million recorded in 2023.
- Peak YoY movement for Enterprise Value: crashed 640.78% in 2021, then surged 81.83% in 2024.
- A 5-year view of Enterprise Value shows it stood at -$70.9 million in 2021, then skyrocketed by 39.15% to -$43.1 million in 2022, then skyrocketed by 45.42% to -$23.6 million in 2023, then soared by 81.83% to -$4.3 million in 2024, then crashed by 56.69% to -$6.7 million in 2025.
- Per Business Quant database, its latest 3 readings for Enterprise Value were -$6.7 million in Q3 2025, -$7.6 million in Q2 2025, and -$7.7 million in Q1 2025.